CoChat
Sign Up
Cited by 17

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Current First-line Therapy for Ovarian Cancer: A Comprehensive Review

Pierce, Stuart R., Clark, Leslie H.·2018·Obstetrical & Gynecological Survey
DOI 10.1097/ogx.0000000000000613
Open this paper in CoChat — free account

Abstract

Importance: Ovarian, fallopian tube, and primary peritoneal cancers constitute the deadliest gynecologic malignancies. After primary cytoreductive surgery, there are several standard first-line cytotoxic treatments for providers to consider. Newer molecular targeted therapies are becoming more common and may have a role as first-line therapy in the future. Objective: This article provides an evidence-based review of all approved standard therapies for first-line treatment of advanced-stage, high-grade serous ovarian cancer. Treatment schedules, dose modifications, and drug substitutions are reviewed. Ongoing trials and pending approvals for newer molecular therapies are discussed. Evidence Acquisition: A comprehensive primary literature review was performed using MEDLINE, the Cochrane Collaborative Database, and PubMed. Guidelines from the National Comprehensive Cancer Network and the Society for Gynecologic Oncology were also reviewed. Results: Seven different approved first-line regimens for high-grade serous ovarian cancer are available based on literature review. These vary in route of administration, dose intensity, drug combinations, and treatment schedules. Molecular targeted therapies, including antiangiogenic drugs and poly(ADP-ribose) polymerase inhibitors, have also been studied in multiple randomized controlled trials in the first-line setting. Conclusions and Relevance: Cytotoxic regimens remain the foundation of first-line treatment for high-grade serous ovarian cancer. Choosing which regimen is best for a patient depends on both patient and disease factors. Molecular therapies in first-line treatment are a promising and exciting possibility, with regulatory approval pending. Target Audience: Obstetricians and gynecologists, family physicians. Learning Objectives: After completing this activity, the learner should be better able to compare the 7 approved up-front cytotoxic regimens for high-grade serous ovarian cancer; choose a regimen based on patient and disease factors; and distinguish 3 molecular therapies that are in clinical trials that may be incorporated into up-front therapy.

Overview

Integrity signals

Registry

Crossref · 10.1097/ogx.0000000000000613

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 1 references

Research works printed but not linked: 44

  1. 2018, Cancer statistics, 2018, CA Cancer J Clin, 68, 7, 10.3322/caac.21442 · DOI
  2. 2006, Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer, Int J Gynaecol Obstet, 95, S161
  3. 2015, Distribution and case-fatality ratios by cell-type for ovarian carcinomas: a 22-year series of 562 patients with uniform current histological classification, Gynecol Oncol, 136, 336, 10.1016/j.ygyno.2014.12.018 · DOI
  4. 1990, Prognostic significance of tumor cell morphometry, histopathology, and clinical parameters in advanced ovarian carcinoma, Int J Gynecol Pathol, 9, 343, 10.1097/00004347-199010000-00006 · DOI
  5. 2012, Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor, Eur J Cancer, 48, 1476, 10.1016/j.ejca.2011.09.023 · DOI
  6. 2016, Inherited mutations in women with ovarian carcinoma, JAMA Oncol, 2, 482, 10.1001/jamaoncol.2015.5495 · DOI
  7. 2012, BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group, J Clin Oncol, 30, 2654, 10.1200/JCO.2011.39.8545 · DOI
  8. 2006, Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada, J Natl Cancer Inst, 98, 1694, 10.1093/jnci/djj465 · DOI
  9. 2008, High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland, Gynecol Oncol, 108, 433, 10.1016/j.ygyno.2007.09.035 · DOI
  10. 1986, A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group study, Cancer, 57, 1725, 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J · DOI
  11. 1989, Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study, J Clin Oncol, 7, 457, 10.1200/JCO.1989.7.4.457 · DOI
  12. 1996, Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group), Semin Oncol, 23, 40
  13. 2003, Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study, J Clin Oncol, 21, 3194, 10.1200/JCO.2003.02.153 · DOI
  14. 2011, Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: NCIC CTG OV.21, Curr Oncol, 18, 84, 10.3747/co.v18i2.725 · DOI
  15. 2016, Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline, Gynecol Oncol, 143, 3, 10.1016/j.ygyno.2016.05.022 · DOI
  16. 2006, Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments, J Natl Cancer Inst, 98, 1655, 10.1093/jnci/djj443 · DOI · Paper page
  17. 2014, Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial, Lancet Oncol, 15, 396, 10.1016/S1470-2045(14)70049-X · DOI
  18. 2002, Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial, Lancet, 360, 505, 10.1016/S0140-6736(02)09738-6 · DOI
  19. 2017, Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer—an NRG Oncology/Gynecologic Oncology Group study, Gynecol Oncol, 144, 459, 10.1016/j.ygyno.2016.11.033 · DOI
  20. 2014, Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis, Pain, 155, 2461, 10.1016/j.pain.2014.09.020 · DOI · Paper page
  21. 2004, Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma, J Natl Cancer Inst, 96, 1682, 10.1093/jnci/djh323 · DOI
  22. 2011, Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial, J Clin Oncol, 29, 3628, 10.1200/JCO.2010.33.8566 · DOI · Paper page
  23. 1993, Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines, Cancer Chemother Pharmacol, 32, 235, 10.1007/BF00685842 · DOI
  24. 2013, Dose-dense chemotherapy improves mechanisms of antitumor immune response, Cancer Res, 73, 119, 10.1158/0008-5472.CAN-12-2225 · DOI
  25. 2009, Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial, Lancet, 374, 1331, 10.1016/S0140-6736(09)61157-0 · DOI
  26. 2013, Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial, Lancet Oncol, 14, 1020, 10.1016/S1470-2045(13)70363-2 · DOI
  27. 2016, Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer, N Engl J Med, 374, 738, 10.1056/NEJMoa1505067 · DOI
  28. 2017, 929O_PRICON8: a GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression-free survival (PFS) analysis, Ann Oncol, 28, 18
  29. 1989, Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy, Cancer Res, 49, 3380
  30. 1996, Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer, N Engl J Med, 335, 1950, 10.1056/NEJM199612263352603 · DOI
  31. 2001, Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group, J Clin Oncol, 19, 1001, 10.1200/JCO.2001.19.4.1001 · DOI
  32. 2006, Intraperitoneal cisplatin and paclitaxel in ovarian cancer, N Engl J Med, 354, 34, 10.1056/NEJMoa052985 · DOI
  33. 2015, Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study, J Clin Oncol, 33, 1460, 10.1200/JCO.2014.55.9898 · DOI
  34. 2016, A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: an NRG Oncology study, Gynecol Oncol, 141, 208
  35. 2014, Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab, J Clin Oncol Am Soc Clin Oncol, 32, 5502
  36. 2018, Hyperthermic intraperitoneal chemotherapy in ovarian cancer, N Engl J Med, 378, 1363
  37. 2011, Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study, Gynecol Oncol, 123, 182, 10.1016/j.ygyno.2011.07.016 · DOI
  38. 2009, An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer, Gynecol Oncol, 113, 63, 10.1016/j.ygyno.2008.12.035 · DOI
  39. 2012, OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer, J Clin Oncol, 30, 2039, 10.1200/JCO.2012.42.0505 · DOI
  40. 2014, Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial, J Clin Oncol, 32, 1302, 10.1200/JCO.2013.51.4489 · DOI
  41. 2011, Incorporation of bevacizumab in the primary treatment of ovarian cancer, N Engl J Med, 365, 2473, 10.1056/NEJMoa1104390 · DOI
  42. 2015, Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study, Gynecol Oncol, 139, 17, 10.1016/j.ygyno.2015.07.103 · DOI
  43. 2011, A phase 3 trial of bevacizumab in ovarian cancer, N Engl J Med, 365, 2484, 10.1056/NEJMoa1103799 · DOI
  44. 2015, Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial, Lancet Oncol, 16, 928, 10.1016/S1470-2045(15)00086-8 · DOI

Cited by

Sorted by citations

See all 17

Metadata

Authors
Pierce, S. R., & Clark, L. H.
Venue
Obstetrical & Gynecological Survey
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2018-11
Volume
73
Issue
11
Pages
650-657
ISSN
  • 1533-9866
  • 0029-7828
DOI
10.1097/ogx.0000000000000613
Cited by
17
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current First-line Therapy for Ovarian Cancer: A Comprehensive Review. https://app.cochat.ai/papers/10.1097/ogx.0000000000000613
The paper
Pierce, S. R., & Clark, L. H. (2018). Current First-line Therapy for Ovarian Cancer: A Comprehensive Review. Obstetrical & Gynecological Survey. https://doi.org/10.1097/ogx.0000000000000613